Introduction
Filgotinib (FIL) is an oral, once-daily, Janus kinase 1 preferential inhibitor (JAKi) approved for the treatment of adults with moderately to severely active ulcerative colitis (UC).1 GALOCEAN (NCT05817942) is an ongoing, European, multicentre, prospective, observational study that aims to investigate the real-world effectiveness and safety of FIL in patients with UC.
Aims & Methods
Here, we present the first interim analysis of the full GALOCEAN cohort. Effectiveness outcomes (partial Mayo Clinic Score [pMCS] and two-item patient reported outcome [PRO2] score), health-related quality of life (HRQoL) outcomes (defined in the Table) and C-reactive protein (CRP) levels were assessed at baseline (BL), week (W) 10 and W24 in the full analysis set, unless otherwise specified. Safety was assessed by documenting adverse events in the safety analysis set. Data are reported as observed.
Results
As of 7 November 2025, 488 enrolled patients had available BL data in the full analysis set (male: 52.3% [n=255]; age, median [min–max]: 37.0 [18–86] years; time since UC diagnosis, median [min–max]: 6.4 [0–39] years). Pancolitis was the most common type of UC (39.3% [n=192]), followed by left-sided colitis (37.9% [n=185]). At BL, over 60% of patients had moderate or severe disease (moderate [pMCS 5–6]: 36.6% [n=173]; severe [pMCS 7–9]: 28.1% [n=133]; 15 patients did not have BL pMCS). The cohort was highly treatment-experienced (73.8% [n=360] had prior advanced treatment, of which 73.2% [n=357] had biologics; 62.5% [n=305] tumour necrosis factor antagonists; 4.9% [n=24] prior JAKi). Furthermore, 23.6% (n=115) of patients were taking systemic corticosteroids at BL. At W10 and W24, 421 and 321 patients had available data, respectively. Effectiveness outcomes, HRQoL outcomes and CRP levels are summarized in the Table. Mean pMCS and PRO2 scores decreased from BL to W10, with further reductions observed at W24. The proportion of patients achieving pMCS or PRO2 remission increased from W10 to W24. Improvements from BL in HRQoL outcomes were also observed at W10 and W24. The median percentage decrease in CRP level from BL to W10 was 35.7%, and 61.6% of patients had a CRP level <3 mg/L at W10. A total of 223 patients (45.7%) had discontinued FIL at W24, mostly owing to a lack of effectiveness (29.1% [n=142]). Overall, 511 patients were included in the safety analysis set. No deaths or major adverse cardiovascular events were reported, and no new safety signals were identified.
Conclusion
This analysis of the full GALOCEAN cohort represents one of the largest real-world studies of patients with UC treated with FIL. Patients were highly treatment-experienced, and approximately one-third had severe disease. Effectiveness outcomes improved following FIL initiation, with approximately 40% and 60% of patients achieving as observed symptomatic remission at W10 and W24, respectively. This was accompanied by improvements from BL in HRQoL outcomes and CRP levels. The discontinuation rate for FIL reported here is in line with previously published real-world data,2 and FIL was generally well tolerated in this refractory population.
![]()
| BL | W10 | W24 |
| Outcome measure | Mean (SD) | Mean (SD) | Mean CFB (SD) | Patients in remission, % (n/N) | Patients with MCID vs BL, % (n/N) | Mean (SD) | Mean CFB (SD) | Patients in remission, % (n/N) | Patients with MCID vs BL, % (n/N) |
| pMCSa,b | 5.5 (1.7) (n=442) | 2.4 (2.4) (n=334) | −3.0 (2.4) (n=334) | 42.5 (145/341) | – | 1.6 (2.2) (n=210) | −3.7 (2.6) (n=210) | 60.3 (129/214) | – |
| PRO2 scorec,d | 3.5 (1.4) (n=439) | 1.4 (1.6) (n=351) | −2.0 (1.8) (n=351) | 40.5 (142/351) | – | 1.0 (1.5) (n=225) | −2.4 (1.9) (n=225) | 55.9 (127/227) | – |
| SIBDQ scoree | 39.6 (12.0) (n=449) | 49.7 (13.0) (n=345) | 9.5 (11.4) (n=327) | – | 52.6 (172/327) | 52.9 (12.4) (n=227) | 11.9 (12.6) (n=214) | – | 60.3 (129/214) |
| Urgency NRS scoref | 4.4 (2.8) (n=426) | 2.7 (2.7) (n=325) | −1.7 (2.9) (n=291) | – | 35.4 (103/291) | 2.5 (2.6) (n=216) | −1.9 (3.1) (n=199) | – | 36.2 (72/199) |
| FACIT-Fatigue scoreg | 29.4 (11.6) (n=449) | 35.2 (11.6) (n=345) | 5.1 (9.6) (n=327) | – | 54.1 (177/327) | 37.2 (10.9) (n=229) | 7.0 (11.0) (n=216) | – | 57.4 (124/216) |
| CRP (mg/L)h | 4.0 (1.1, 10.0) (n=344) | 1.4 (0.8, 4.0) (n=281) | −1.0 (−5.2,0.0) (n=216) | – | – | N/Ri | N/Ri | – | – |
Data are presented for the full analysis set, which comprised all patients who initiated up to and including FIL 200 mg with available BL data. Data are reported as observed for patients who remained on FIL, remained in the study and reached the relevant study visit. N numbers shown are the number of patients who reached the visit and had been assessed for the specified outcome measure. aExcludes patients with inactive disease at initiation of FIL (pMCS ≤1). bpMCS remission was defined as a pMCS of ≤1, with rectal bleeding, stool frequency and Physician's Global Assessment subscores of ≤1. cExcludes patients with inactive disease at initiation of FIL (PRO2 score=0). dPRO2 remission was defined as rectal bleeding and stool frequency subscores of 0. eMCID was defined as an increase from baseline of ≥9. fMCID was defined as a reduction from baseline of ≥3. gMCID was defined as an increase from baseline of ≥4. hFor CRP, values presented are medians (Q1-Q3) instead of means (SD). iCRP levels were measured at BL, W10 and W24; data are reported up to W10 owing to missing data at W24. BL, baseline; CFB, change from baseline; CRP, C-reactive protein; FACIT, Functional Assessment of Chronic Illness Therapy; FIL, filgotinib; MCID, minimal clinically important difference; N/R not reported; NRS, numeric rating scale; pMCS, partial Mayo Clinic Score; PRO2, two-item patient reported outcome; SD, standard deviation; SIBDQ, Short Inflammatory Bowel Disease Questionnaire; W, week. |
References
1. Alfasigma S.p.A. Summary of product characteristics, Jyseleca. EMA, 2025. Accessed 30 March 2026. https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_en.pdf.
2. Akiyama S et al. Aliment Pharmacol Ther 2025;61:524–37.
Disclosure
The GALOCEAN study is sponsored by Alfasigma S.p.A., who funded these analyses. Medical writing support was provided by PharmaGenesis London, UK, and was funded by Alfasigma S.p.A.
ML reports consultancy/lecture fees from AbbVie, Bristol Myers Squibb, Eli Lilly, Galapagos, Janssen-Cilag, Johnson & Johnson, Medtronic, Pfizer, Takeda and Tillotts Pharma; and grants from Alfasigma, Galapagos, the Netherlands Federation of University Medical Centres, the Netherlands Organisation for Health Research and Development (ZonMw) and the Top Consortia for Knowledge and Innovation (TKI).
ER reports speaker fees from AbbVie, Faes Farma, Ferring Pharmaceuticals, Galapagos, Janssen Pharmaceuticals, Kern Pharma, MSD, Pfizer and Takeda; and consultancy fees from AbbVie, Eli Lilly, Fresenius Kabi, Galapagos, Janssen Pharmaceuticals, MSD and Pfizer.
JPS reports speaker fees from AbbVie, Alfasigma, Amgen, AstraZeneca, Bristol Myers Squibb, Eisai Pharma, Fresenius Kabi, Janssen-Cilag, Pfizer, Pharmacosmos UK, Takeda UK and Tillotts Pharma UK; and advisory board fees from AbbVie, Dr. Falk Pharma (UK) and Galapagos.
MLH reports research grants, speaker fees and/or advisory board fees from AbbVie, Eli Lilly, Ferring Pharmaceuticals, Galapagos, Janssen Pharmaceuticals, MSD, Pfizer, Takeda, Tillotts Pharma and Viatris (formerly Meda).
CGdSJ reports speaker and/or consultancy fees from AbbVie, Alfasigma, Amgen, Celltrion, Ferring Pharmaceuticals, Galapagos, Janssen Pharmaceuticals, MSD, Pfizer and Takeda.
WR reports speaker and/or consultancy fees from AbbVie, Amgen, AOP Health (formerly AOP Orphan), Boehringer Ingelheim, Bristol Myers Squibb, Calyx, Celltrion, Eli Lilly, Ferring Pharmaceuticals, Galapagos, Gilead Sciences, InDex Pharmaceuticals, Janssen Pharmaceuticals, MedAhead, MEDICE, Microbiotica, MSD, Pfizer, Roche, Sobi and Takeda; advisory board fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Galapagos, Janssen Pharmaceuticals and Pfizer; and research funding from AbbVie, Janssen Pharmaceuticals, Sandoz, Sanofi and Takeda.
AA reports consultancy and/or advisory board fees from AbbVie, Alfasigma, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring Pharmaceuticals, Galapagos, Gilead Sciences, Giuliani, Janssen Pharmaceuticals, LIONHEALTH Benefit Society, Merck, Nestlé, Pfizer, Roche, Samsung Bioepis, Sandoz, Sanofi, Takeda and Tillotts Pharma; lecture and/or speaker bureau fees from AbbVie, AG Pharma, Alfasigma, Biogen, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring Pharmaceuticals, Galapagos, Gilead Sciences, Janssen Pharmaceuticals, LIONHEALTH Benefit Society, Merck, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda and Teva Pharmaceuticals; and research grants from Biogen, MSD, Pfizer and Takeda.
GD reports research/educational grants and/or speaker/personal fees from Abbott, AbbVie, Amgen, Bristol Myers Squibb, Celltrion, Dr. Falk Pharma, Galapagos, Genuity Science, Gilead Sciences, Janssen Pharmaceuticals, MSD, Pfizer, Takeda/Shire and Tillotts Pharma.
SV reports financial support for research from AbbVie, Galapagos, Johnson & Johnson, Pfizer and Takeda; speaker and/or consultancy fees from AbbVie, Abivax, AbolerIS Pharma, Agomab Therapeutics, Alimentiv (formerly Robarts Clinical Trials), Arena Pharmaceuticals, AstraZeneca, Biora Therapeutics (formerly Progenity), Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cytoki Pharma, Dr. Falk Pharma, Eli Lilly, Ferring Pharmaceuticals, Galapagos, Genentech-Roche, Gilead Sciences, GSK, Hospira, IMIDomics, Janssen Pharmaceuticals, Johnson & Johnson, Materia Prima, Mestag Therapeutics, MiroBio, Morphic Therapeutic, MRM Health, MSD, Mundipharma, Pfizer, ProDigest, Prometheus Biosciences, Surrozen, Takeda, Theravance Biopharma, Tillotts Pharma, VectivBio, Ventyx Biosciences and Zealand Pharma; and participation on a data safety monitoring board for Sanofi.
RS reports no financial disclosures or conflicts of interest.
JL is an employee of Intercept Pharmaceuticals, Alfasigma Group.
AO and CL are employees of Alfasigma S.p.A.
VS is a consultant funded by Alfasigma S.p.A.
SS reports personal fees from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Dr. Falk Pharma, Eli Lilly, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos/Gilead Sciences, Hikma Pharmaceuticals, I-Mab, Janssen Pharmaceuticals, Morphic Therapeutic, MSD, Mylan, Pfizer, Protagonist Therapeutics, Provention Bio, Sandoz/Hexal, Takeda, Theravance Biopharma and Ventyx Biosciences; and funding from the Deutsche Forschungsgemeinschaft Excellence Cluster.